{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:42:10Z","timestamp":1788914530034,"version":"build-2803163510"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2024-I2M-3-014"],"award-info":[{"award-number":["2024-I2M-3-014"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08077-2","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T10:47:04Z","timestamp":1776163624000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting MET in non-small cell lung cancer brain metastases: from molecular mechanism to precision therapy"],"prefix":"10.1186","volume":"24","author":[{"given":"Xinyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengchun","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"8077_CR1","first-page":"1","volume":"28","author":"Lung Cancer Medical Education Committee of Chinese Medical Education Association & Brain Metastasis Collaboration Group, Youth Specialists Committee of Lung Cancer of Beijing Medical Reward Foundation","year":"2025","unstructured":"Lung Cancer Medical Education Committee of Chinese Medical Education Association & Brain Metastasis Collaboration Group, Youth Specialists Committee of Lung Cancer of Beijing Medical Reward Foundation. [Clinical Practice Guidelines for the Management of Brain Metastases from Non-small Cell Lung Cancer with Actionable Gene Alterations in China (2025 Edition)]. Zhongguo Fei Ai Za Zhi. 2025;28:1\u201321.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"8077_CR2","doi-asserted-by":"crossref","unstructured":"Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22:2865\u201372.","DOI":"10.1200\/JCO.2004.12.149"},{"key":"8077_CR3","doi-asserted-by":"crossref","unstructured":"Bogdanska W, Paik PK. From knowledge to action: the journey toward targeting the MET pathway via MET exon 14 skipping. Cancer. 2025;131:e35782.","DOI":"10.1002\/cncr.35782"},{"key":"8077_CR4","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3171\/2021.9.JNS212150","volume":"137","author":"D London","year":"2022","unstructured":"London D, et al. The incidence and predictors of new brain metastases in patients with non-small cell lung cancer following discontinuation of systemic therapy. J Neurosurg. 2022;137:544\u201354.","journal-title":"J Neurosurg"},{"key":"8077_CR5","doi-asserted-by":"crossref","unstructured":"Tatineni V, O'Shea PJ, Rauf Y, Jia X, Murphy ES, Chao ST, Suh JH, Peereboom D, Ahluwalia M. Outcomes of BRAF, MET, RET, and ROS1 mutated non-small cell lung cancer with brain metastases (NSCLCBM). Int J Radiat Oncol Biol Phys. 2021;111:e582\u201383. https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0360301621024","DOI":"10.1016\/j.ijrobp.2021.07.1563"},{"key":"8077_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12890-024-02841-0","volume":"24","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Long-term trends of lung cancer incidence and survival in southeastern China, 2011\u20132020: a population-based study. BMC Pulm Med. 2024;24:25.","journal-title":"BMC Pulm Med"},{"key":"8077_CR7","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1200\/JCO.20.01255","volume":"38","author":"PW Sperduto","year":"2020","unstructured":"Sperduto PW, et al. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020;38:3773\u201384.","journal-title":"J Clin Oncol"},{"key":"8077_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.nbd.2009.07.029","volume":"37","author":"The role of","year":"2010","unstructured":"Palmer AM. The role of the blood\u2013CNS barrier in CNS disorders and their treatment. Neurobiol Dis. 2010;37:3\u201312.","journal-title":"Neurobiol Dis"},{"key":"8077_CR9","doi-asserted-by":"crossref","unstructured":"Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis. 2010;37:13\u201325.","DOI":"10.1016\/j.nbd.2009.07.030"},{"key":"8077_CR10","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JOP.19.00357","volume":"15","author":"V Ernani","year":"2019","unstructured":"Ernani V, Stinchcombe TE. Management of Brain Metastases in Non\u2013Small-Cell Lung Cancer. J Oncol Pract. 2019;15:563.","journal-title":"J Oncol Pract"},{"key":"8077_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1080\/02841860510029699","volume":"44","author":"L Kepka","year":"2005","unstructured":"Kepka L, Cieslak E, Bujko K, Fijuth J, Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol. 2005;44:389\u201398.","journal-title":"Acta Oncol"},{"key":"8077_CR12","doi-asserted-by":"crossref","unstructured":"Karlsson AT, Hjermstad MJ, Aass N, Skovlund E, Kaasa S, Yri OE. Overall survival after radiotherapy for brain metastases according to ECOG status: a prospective study of 294 NSCLC patients. Cancers (Basel). 2024;16:1486.","DOI":"10.3390\/cancers16081486"},{"key":"8077_CR13","doi-asserted-by":"crossref","unstructured":"Cho BC, Ahn MJ, Kang JH, Soo RA, Reungwetwattana T, Yang JCH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41:4208\u201317.","DOI":"10.1200\/JCO.23.00515"},{"key":"8077_CR14","doi-asserted-by":"crossref","unstructured":"Shi Y, Wu L, Ji Y, Chen G, Li B, Bi M, et al. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial. Lancet Respir Med. 2025;13:677\u201386.","DOI":"10.1016\/S2213-2600(25)00121-3"},{"key":"8077_CR15","doi-asserted-by":"crossref","unstructured":"Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020;38:538\u201347.","DOI":"10.1200\/JCO.19.00457"},{"key":"8077_CR16","doi-asserted-by":"crossref","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325.","DOI":"10.1056\/NEJMoa1713137"},{"key":"8077_CR17","first-page":"81","volume":"28","author":"J CHEN","year":"2025","unstructured":"CHEN J, HAN B, HU Y. & Cancer Specialty Committee of Chinese Elderly Health Care Association, L. MET\u5f02\u5e38NSCLC\u8bca\u7597\u4e13\u5bb6\u5171\u8bc6(2025\u7248). Zhongguo Fei Ai Za Zhi. 2025;28:81\u201394.","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"8077_CR18","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41571-025-01085-z","volume":"23","author":"J Zhao","year":"2026","unstructured":"Zhao J, et al. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches. Nat Rev Clin Oncol. 2026;23:63\u201383.","journal-title":"Nat Rev Clin Oncol"},{"key":"8077_CR19","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1177\/1758834011422556","volume":"3","author":"SL Organ","year":"2011","unstructured":"Organ SL, Tsao M-S. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011;3:S7\u201319.","journal-title":"Ther Adv Med Oncol"},{"key":"8077_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, et al. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:45.","journal-title":"Mol Cancer"},{"key":"8077_CR21","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fcell.2020.00055","volume":"8","author":"H Wang","year":"2020","unstructured":"Wang H, et al. The Function of the HGF\/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol. 2020;8:55.","journal-title":"Front Cell Dev Biol"},{"key":"8077_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","volume":"24","author":"J Mazieres","year":"2023","unstructured":"Mazieres J, et al. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes. Clin Lung Cancer. 2023;24:483\u201397.","journal-title":"Clin Lung Cancer"},{"key":"8077_CR23","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","volume":"17","author":"R Guo","year":"2020","unstructured":"Guo R, et al. MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020;17:569\u201387.","journal-title":"Nat Rev Clin Oncol"},{"key":"8077_CR24","doi-asserted-by":"publisher","first-page":"107897","DOI":"10.1016\/j.lungcan.2024.107897","volume":"194","author":"Q Zheng","year":"2024","unstructured":"Zheng Q, et al. NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: A prospective, multicenter study in China. Lung Cancer. 2024;194:107897.","journal-title":"Lung Cancer"},{"key":"8077_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.lungcan.2020.04.040","volume":"145","author":"M Zhuo","year":"2020","unstructured":"Zhuo M, et al. Analysis of MET kinase domain rearrangement in NSCLC. Lung Cancer. 2020;145:140\u20133.","journal-title":"Lung Cancer"},{"key":"8077_CR26","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13000-015-0362-5","volume":"10","author":"I Watermann","year":"2015","unstructured":"Watermann I, et al. Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation? Diagn Pathol. 2015;10:130.","journal-title":"Diagn Pathol"},{"key":"8077_CR27","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s00103-019-02996-w","volume":"62","author":"M Rosset","year":"2019","unstructured":"Rosset M, Reifegerste D, Baumann E, Kludt E, Weg-Remers S. [Trends in cancer information services over 25 years: An analysis of inquiries from patients and relatives made to the Cancer Information Service of the German Cancer Research Center from 1992 to 2016]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:1120\u20138.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"8077_CR28","doi-asserted-by":"publisher","first-page":"6926","DOI":"10.1038\/s41598-025-85631-w","volume":"15","author":"Z Liu","year":"2025","unstructured":"Liu Z, et al. Molecular mechanism of type ib MET inhibitors and their potential for CNS tumors. Sci Rep. 2025;15:6926.","journal-title":"Sci Rep"},{"key":"8077_CR29","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2353\/ajpath.2010.090863","volume":"177","author":"E Benedettini","year":"2010","unstructured":"Benedettini E, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 2010;177:415\u201323.","journal-title":"Am J Pathol"},{"key":"8077_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1158\/1078-0432.CCR-21-1566","volume":"28","author":"LN Mathieu","year":"2022","unstructured":"Mathieu LN, et al. FDA Approval Summary: Capmatinib and Tepotinib for the Treatment of Metastatic NSCLC Harboring MET Exon 14 Skipping Mutations or Alterations. Clin Cancer Res. 2022;28:249\u201354.","journal-title":"Clin Cancer Res"},{"key":"8077_CR31","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/oncolo\/oyac094","volume":"27","author":"RSP Huang","year":"2022","unstructured":"Huang RSP, et al. Clinicopathologic and Genomic Landscape of Non-Small Cell Lung Cancer Brain Metastases. Oncologist. 2022;27:839\u201348.","journal-title":"Oncologist"},{"key":"8077_CR32","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1038\/s41467-023-40793-x","volume":"14","author":"A Skakodub","year":"2023","unstructured":"Skakodub A, et al. Genomic analysis and clinical correlations of non-small cell lung cancer brain metastasis. Nat Commun. 2023;14:4980.","journal-title":"Nat Commun"},{"key":"8077_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou F, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22:95\u2013116.","journal-title":"Nat Rev Clin Oncol"},{"key":"8077_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro A, J\u00e4nne PA, Mok T, Peters S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat Cancer. 2021;2:377\u201391.","journal-title":"Nat Cancer"},{"key":"8077_CR35","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1177\/1758834011422557","volume":"3","author":"JR Sierra","year":"2011","unstructured":"Sierra JR, Tsao M-S. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3:S21\u201335.","journal-title":"Ther Adv Med Oncol"},{"issue":"Suppl 1","key":"8077_CR36","doi-asserted-by":"publisher","first-page":"e35782","DOI":"10.1002\/cncr.35782","volume":"131","author":"W Bogdanska","year":"2025","unstructured":"Bogdanska W, Paik PK. From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skipping. Cancer. 2025;131(Suppl 1):e35782.","journal-title":"Cancer"},{"key":"8077_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jtho.2016.05.005","volume":"11","author":"N Van Der Steen","year":"2016","unstructured":"Van Der Steen N, et al. cMET Exon 14 Skipping: From the Structure to the Clinic. J Thorac Oncol. 2016;11:1423\u201332.","journal-title":"J Thorac Oncol"},{"key":"8077_CR38","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S1097-2765(01)00378-1","volume":"8","author":"P Peschard","year":"2001","unstructured":"Peschard P, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995\u20131004.","journal-title":"Mol Cell"},{"key":"8077_CR39","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.devcel.2011.05.007","volume":"20","author":"CA Parachoniak","year":"2011","unstructured":"Parachoniak CA, Luo Y, Abella JV, Keen JH, Park M. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell. 2011;20:751\u201363.","journal-title":"Dev Cell"},{"key":"8077_CR40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0092-8674(94)90318-2","volume":"77","author":"C Ponzetto","year":"1994","unstructured":"Ponzetto C, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor\/scatter factor receptor family. Cell. 1994;77:261\u201371.","journal-title":"Cell"},{"key":"8077_CR41","first-page":"1631","volume":"10","author":"G Pelicci","year":"1995","unstructured":"Pelicci G, et al. The motogenic and mitogenic responses to HGF are amplified by the Shc adaptor protein. Oncogene. 1995;10:1631\u20138.","journal-title":"Oncogene"},{"key":"8077_CR42","doi-asserted-by":"publisher","first-page":"13116","DOI":"10.1074\/jbc.271.22.13116","volume":"271","author":"ED Fixman","year":"1996","unstructured":"Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the tpr-Met oncoprotein. J Biol Chem. 1996;271:13116\u201322.","journal-title":"J Biol Chem"},{"key":"8077_CR43","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/34657","volume":"391","author":"C Boccaccio","year":"1998","unstructured":"Boccaccio C, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature. 1998;391:285\u20138.","journal-title":"Nature"},{"key":"8077_CR44","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/sj.onc.1205004","volume":"21","author":"Y-W Zhang","year":"2002","unstructured":"Zhang Y-W, Wang L-M, Jove R. Vande Woude, G. F. Requirement of Stat3 signaling for HGF\/SF-Met mediated tumorigenesis. Oncogene. 2002;21:217\u201326.","journal-title":"Oncogene"},{"key":"8077_CR45","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1083\/jcb.149.7.1419","volume":"149","author":"U Schaeper","year":"2000","unstructured":"Schaeper U, et al. Coupling of Gab1 to c-Met, Grb2, and Shp2 mediates biological responses. J Cell Biol. 2000;149:1419\u201332.","journal-title":"J Cell Biol"},{"key":"8077_CR46","doi-asserted-by":"publisher","first-page":"31536","DOI":"10.1074\/jbc.M003597200","volume":"275","author":"LS Lock","year":"2000","unstructured":"Lock LS, Royal I, Naujokas MA, Park M. Identification of an atypical Grb2 carboxyl-terminal SH3 domain binding site in Gab docking proteins reveals Grb2-dependent and -independent recruitment of Gab1 to receptor tyrosine kinases. J Biol Chem. 2000;275:31536\u201345.","journal-title":"J Biol Chem"},{"key":"8077_CR47","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1126\/science.1072682","volume":"298","author":"GL Johnson","year":"2002","unstructured":"Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science. 2002;298:1911\u20132.","journal-title":"Science"},{"key":"8077_CR48","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1093\/emboj\/16.10.2634","volume":"16","author":"GA Rodrigues","year":"1997","unstructured":"Rodrigues GA, Park M, Schlessinger J. Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 1997;16:2634\u201345.","journal-title":"EMBO J"},{"key":"8077_CR49","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1038\/sj.onc.1203977","volume":"19","author":"L Lamorte","year":"2000","unstructured":"Lamorte L, Kamikura DM, Park M. A switch from p130Cas\/Crk to Gab1\/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein. Oncogene. 2000;19:5973\u201381.","journal-title":"Oncogene"},{"key":"8077_CR50","doi-asserted-by":"crossref","unstructured":"Recio JA, Merlino G. Hepatocyte growth factor\/scatter factor activates proliferation in melanoma cells through p38 MAPK, ATF-2 and cyclin D1. Oncogene. 2002;21:1000\u20131008.","DOI":"10.1038\/sj.onc.1205150"},{"key":"8077_CR51","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1158\/0008-5472.CAN-03-2383","volume":"64","author":"A Rasola","year":"2004","unstructured":"Rasola A, et al. Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res. 2004;64:1744\u201350.","journal-title":"Cancer Res"},{"key":"8077_CR52","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1002\/ijc.21766","volume":"118","author":"N Coltella","year":"2006","unstructured":"Coltella N, et al. p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. Int J Cancer. 2006;118:2981\u201390.","journal-title":"Int J Cancer"},{"key":"8077_CR53","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/nrc2664","volume":"9","author":"JA Engelman","year":"2009","unstructured":"Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9:550\u201362.","journal-title":"Nat Rev Cancer"},{"key":"8077_CR54","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","volume":"129","author":"BD Manning","year":"2007","unstructured":"Manning BD, Cantley LC. AKT\/PKB signaling: navigating downstream. Cell. 2007;129:1261\u201374.","journal-title":"Cell"},{"key":"8077_CR55","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1128\/MCB.22.4.1060-1072.2002","volume":"22","author":"M M\u00fcller","year":"2002","unstructured":"M\u00fcller M, Morotti A, Ponzetto C. Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002;22:1060\u201372.","journal-title":"Mol Cell Biol"},{"key":"8077_CR56","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrc780","volume":"2","author":"M Karin","year":"2002","unstructured":"Karin M, Cao Y, Greten FR, Li Z-W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer. 2002;2:301\u201310.","journal-title":"Nat Rev Cancer"},{"key":"8077_CR57","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1038\/sj.onc.1208327","volume":"24","author":"S Fan","year":"2005","unstructured":"Fan S, et al. Role of NF-kappaB signaling in hepatocyte growth factor\/scatter factor-mediated cell protection. Oncogene. 2005;24:1749\u201366.","journal-title":"Oncogene"},{"key":"8077_CR58","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","volume":"20","author":"CR Maroun","year":"2000","unstructured":"Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20:8513\u201325.","journal-title":"Mol Cell Biol"},{"key":"8077_CR59","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massagu\u00e9 J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9:274\u201384.","journal-title":"Nat Rev Cancer"},{"key":"8077_CR60","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/nrc3053","volume":"11","author":"PS Steeg","year":"2011","unstructured":"Steeg PS, Camphausen KA, Smith QR. Brain metastases as preventive and therapeutic targets. Nat Rev Cancer. 2011;11:352\u201363.","journal-title":"Nat Rev Cancer"},{"key":"8077_CR61","first-page":"2353","volume":"33","author":"W Jia","year":"2013","unstructured":"Jia W, Martin TA, Zhang G, Jiang WG. Junctional adhesion molecules in cerebral endothelial tight junction and brain metastasis. Anticancer Res. 2013;33:2353\u20139.","journal-title":"Anticancer Res"},{"key":"8077_CR62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00281-009-0177-0","volume":"31","author":"B Engelhardt","year":"2009","unstructured":"Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. Semin Immunopathol. 2009;31:497\u2013511.","journal-title":"Semin Immunopathol"},{"key":"8077_CR63","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.bbcan.2017.03.004","volume":"1868","author":"T Cust\u00f3dio-Santos","year":"2017","unstructured":"Cust\u00f3dio-Santos T, Videira M, Brito MA. Brain metastasization of breast cancer. Biochim Biophys Acta Rev Cancer. 2017;1868:132\u201347.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8077_CR64","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13046-024-03015-w","volume":"43","author":"S Xia","year":"2024","unstructured":"Xia S, et al. Mesothelin promotes brain metastasis of non-small cell lung cancer by activating MET. J Experimental Clin Cancer Research: CR. 2024;43:103.","journal-title":"J Experimental Clin Cancer Research: CR"},{"key":"8077_CR65","doi-asserted-by":"crossref","unstructured":"Yao S, Liu F, Hou Y, Yu Z, Jiang H. Unveiling the role of HGF\/c-Met signaling in non-small cell lung cancer tumor microenvironment. Cancer Med. 2024;13:e70191.","DOI":"10.3390\/ijms25169101"},{"key":"8077_CR66","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1158\/0008-5472.CAN-12-3775","volume":"73","author":"JL Breindel","year":"2013","unstructured":"Breindel JL, et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013;73:5053\u201365.","journal-title":"Cancer Res"},{"key":"8077_CR67","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H, et al. Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer. 2017;17:302\u201317.","journal-title":"Nat Rev Cancer"},{"key":"8077_CR68","doi-asserted-by":"publisher","first-page":"5287","DOI":"10.1158\/1078-0432.CCR-15-1836","volume":"22","author":"LT Lyle","year":"2016","unstructured":"Lyle LT, et al. Alterations in Pericyte Subpopulations Are Associated with Elevated Blood-Tumor Barrier Permeability in Experimental Brain Metastasis of Breast Cancer. Clin Cancer Res. 2016;22:5287\u201399.","journal-title":"Clin Cancer Res"},{"key":"8077_CR69","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1158\/2159-8290.CD-19-1228","volume":"10","author":"B Ngo","year":"2020","unstructured":"Ngo B, et al. Limited Environmental Serine and Glycine Confer Brain Metastasis Sensitivity to PHGDH Inhibition. Cancer Discov. 2020;10:1352\u201373.","journal-title":"Cancer Discov"},{"key":"8077_CR70","doi-asserted-by":"publisher","first-page":"e50635","DOI":"10.15252\/embr.202050635","volume":"21","author":"P Altea-Manzano","year":"2020","unstructured":"Altea-Manzano P, Cuadros AM, Broadfield LA, Fendt S-M. Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take. EMBO Rep. 2020;21:e50635.","journal-title":"EMBO Rep"},{"key":"8077_CR71","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/0008-5472.CAN-14-2268","volume":"75","author":"J Chen","year":"2015","unstructured":"Chen J, et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 2015;75:554\u201365.","journal-title":"Cancer Res"},{"key":"8077_CR72","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cell.2014.01.040","volume":"156","author":"M Valiente","year":"2014","unstructured":"Valiente M, et al. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156:1002\u201316.","journal-title":"Cell"},{"key":"8077_CR73","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-022-05680-3","volume":"614","author":"E Karimi","year":"2023","unstructured":"Karimi E, et al. Single-cell spatial immune landscapes of primary and metastatic brain tumours. Nature. 2023;614:555\u201363.","journal-title":"Nature"},{"key":"8077_CR74","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13046-024-03020-z","volume":"43","author":"S Schneegans","year":"2024","unstructured":"Schneegans S, et al. HERC5 downregulation in non-small cell lung cancer is associated with altered energy metabolism and metastasis. J Exp Clin Cancer Res. 2024;43:110.","journal-title":"J Exp Clin Cancer Res"},{"key":"8077_CR75","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/ijms21020471","volume":"21","author":"V Boschert","year":"2020","unstructured":"Boschert V, et al. The Influence of Met Receptor Level on HGF-Induced Glycolytic Reprogramming in Head and Neck Squamous Cell Carcinoma. Int J Mol Sci. 2020;21:471.","journal-title":"Int J Mol Sci"},{"key":"8077_CR76","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1038\/nrd2530","volume":"7","author":"PM Comoglio","year":"2008","unstructured":"Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7:504\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"8077_CR77","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/nrm3012","volume":"11","author":"L Trusolino","year":"2010","unstructured":"Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11:834\u201348.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8077_CR78","doi-asserted-by":"publisher","first-page":"ra80","DOI":"10.1126\/scisignal.2000643","volume":"2","author":"A Bertotti","year":"2009","unstructured":"Bertotti A, et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal. 2009;2:ra80.","journal-title":"Sci Signal"},{"key":"8077_CR79","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fmolb.2018.00086","volume":"5","author":"A Hervieu","year":"2018","unstructured":"Hervieu A, Kermorgant S. The Role of PI3K in Met Driven Cancer: A Recap. Front Mol Biosci. 2018;5:86.","journal-title":"Front Mol Biosci"},{"key":"8077_CR80","doi-asserted-by":"publisher","first-page":"4970","DOI":"10.1158\/0008-5472.CAN-15-3541","volume":"76","author":"F Xing","year":"2016","unstructured":"Xing F, et al. Activation of the c-Met Pathway Mobilizes an Inflammatory Network in the Brain Microenvironment to Promote Brain Metastasis of Breast Cancer. Cancer Res. 2016;76:4970\u201380.","journal-title":"Cancer Res"},{"key":"8077_CR81","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s00401-024-02694-1","volume":"147","author":"T Redmer","year":"2024","unstructured":"Redmer T, et al. MET receptor serves as a promising target in melanoma brain metastases. Acta Neuropathol. 2024;147:44.","journal-title":"Acta Neuropathol"},{"key":"8077_CR82","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","volume":"25","author":"R Benayed","year":"2019","unstructured":"Benayed R, et al. High Yield of RNA Sequencing for Targetable Kinase Fusions in Lung Adenocarcinomas with No Mitogenic Driver Alteration Detected by DNA Sequencing and Low Tumor Mutation Burden. Clin Cancer Res. 2019;25:4712\u201322.","journal-title":"Clin Cancer Res"},{"key":"8077_CR83","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","volume":"16","author":"W Li","year":"2021","unstructured":"Li W, et al. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC. J Thorac Oncol. 2021;16:404\u201318.","journal-title":"J Thorac Oncol"},{"key":"8077_CR84","doi-asserted-by":"publisher","first-page":"e2442970","DOI":"10.1001\/jamanetworkopen.2024.42970","volume":"7","author":"D Owen","year":"2024","unstructured":"Owen D, et al. Actionable Structural Variant Detection via RNA-NGS and DNA-NGS in Patients With Advanced Non-Small Cell Lung Cancer. JAMA Netw Open. 2024;7:e2442970.","journal-title":"JAMA Netw Open"},{"key":"8077_CR85","doi-asserted-by":"publisher","first-page":"544680","DOI":"10.3389\/fneur.2020.544680","volume":"11","author":"LA Ramkissoon","year":"2020","unstructured":"Ramkissoon LA, et al. Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Front Neurol. 2020;11:544680.","journal-title":"Front Neurol"},{"key":"8077_CR86","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/1759-7714.13300","volume":"11","author":"C Ma","year":"2020","unstructured":"Ma C, et al. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples. Thorac Cancer. 2020;11:588\u201393.","journal-title":"Thorac Cancer"},{"key":"8077_CR87","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L De Mattos-Arruda","year":"2015","unstructured":"De Mattos-Arruda L, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.","journal-title":"Nat Commun"},{"key":"8077_CR88","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12916-022-02595-8","volume":"20","author":"M Li","year":"2022","unstructured":"Li M, et al. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028). BMC Med. 2022;20:398.","journal-title":"BMC Med"},{"key":"8077_CR89","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/978-3-030-35805-1_7","volume":"1220","author":"R Pi\u00f1eiro","year":"2020","unstructured":"Pi\u00f1eiro R, Mart\u00ednez-Pena I, L\u00f3pez-L\u00f3pez R. Relevance of CTC Clusters in Breast Cancer Metastasis. Adv Exp Med Biol. 2020;1220:93\u2013115.","journal-title":"Adv Exp Med Biol"},{"key":"8077_CR90","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1093\/annonc\/mdv288","volume":"26","author":"H Yoshioka","year":"2015","unstructured":"Yoshioka H, et al. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB\/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study). Ann Oncol. 2015;26:2066\u201372.","journal-title":"Ann Oncol"},{"key":"8077_CR91","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8000","author":"DR Spigel","year":"2014","unstructured":"Spigel DR, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/jco.2014.32.15_suppl.8000.","journal-title":"J Clin Oncol"},{"key":"8077_CR92","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1200\/JCO.2014.60.7317","volume":"33","author":"G Scagliotti","year":"2015","unstructured":"Scagliotti G, et al. Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015;33:2667\u201374. Phase III Multinational, Randomized.","journal-title":"J Clin Oncol"},{"key":"8077_CR93","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1056\/NEJMoa2002787","volume":"383","author":"J Wolf","year":"2020","unstructured":"Wolf J, et al. Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383:944\u201357.","journal-title":"N Engl J Med"},{"key":"8077_CR94","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1016\/j.jtho.2018.08.008","volume":"13","author":"X Mignard","year":"2018","unstructured":"Mignard X, et al. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas. J Thorac Oncol. 2018;13:1962\u20137.","journal-title":"J Thorac Oncol"},{"key":"8077_CR95","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2018.79.3455","volume":"36","author":"D Planchard","year":"2018","unstructured":"Planchard D. Have We Really MET a New Target? JCO. 2018;36:3069\u201371.","journal-title":"JCO"},{"key":"8077_CR96","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.lungcan.2017.07.021","volume":"111","author":"L Bubendorf","year":"2017","unstructured":"Bubendorf L, et al. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. Lung Cancer. 2017;111:143\u20139.","journal-title":"Lung Cancer"},{"key":"8077_CR97","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","volume":"8","author":"Y-L Wu","year":"2020","unstructured":"Wu Y-L, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial. Lancet Respir Med. 2020;8:1132\u201343.","journal-title":"Lancet Respir Med"},{"key":"8077_CR98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.lungcan.2016.11.011","volume":"103","author":"T Reungwetwattana","year":"2017","unstructured":"Reungwetwattana T, Liang Y, Zhu V, Ou S-H. I. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer. 2017;103:27\u201337.","journal-title":"Lung Cancer"},{"key":"8077_CR99","doi-asserted-by":"crossref","unstructured":"Backes AC, Zech B, Felber B, Klebl B, M\u00fcller G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition. Expert Opin Drug Discov. 2008;3:1427\u201349.","DOI":"10.1517\/17460440802580106"},{"key":"8077_CR100","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","volume":"18","author":"J Remon","year":"2023","unstructured":"Remon J, et al. MET alterations in NSCLC-Current Perspectives and Future Challenges. J Thorac Oncol. 2023;18:419\u201335.","journal-title":"J Thorac Oncol"},{"key":"8077_CR101","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","volume":"25","author":"Y-L Wu","year":"2024","unstructured":"Wu Y-L, et al. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2024;25:989\u20131002.","journal-title":"Lancet Oncol"},{"key":"8077_CR102","unstructured":"Gadgeel SM, Park K, Kim SW, et al. Amivantamab plus lazertinib vs osimertinib in first-line EGFR-mutant advanced NSCLC: longer follow-up of the MARIPOSA study. In: Abstract OA.02.03. International Association for the Study of Lung Cancer (IASLC), San Diego, CA, USA, 2024."},{"key":"8077_CR103","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JC-H Yang","year":"2025","unstructured":"Yang JC-H, et al. Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2025;393:1681\u201393.","journal-title":"N Engl J Med"},{"key":"8077_CR104","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","volume":"35","author":"A Passaro","year":"2024","unstructured":"Passaro A, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2024;35:77\u201390.","journal-title":"Ann Oncol"},{"key":"8077_CR105","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1124\/mol.114.096065","volume":"87","author":"K-A Jung","year":"2015","unstructured":"Jung K-A, Choi B-H, Kwak M-K. The c-MET\/PI3K signaling is associated with cancer resistance to doxorubicin and photodynamic therapy by elevating BCRP\/ABCG2 expression. Mol Pharmacol. 2015;87:465\u201376.","journal-title":"Mol Pharmacol"},{"key":"8077_CR106","doi-asserted-by":"publisher","first-page":"24510","DOI":"10.18632\/oncotarget.8229","volume":"7","author":"Q-Y Chen","year":"2016","unstructured":"Chen Q-Y, et al. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET. Oncotarget. 2016;7:24510\u201326.","journal-title":"Oncotarget"},{"key":"8077_CR107","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12885-015-1064-9","volume":"15","author":"F Brandes","year":"2015","unstructured":"Brandes F, et al. Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model. BMC Cancer. 2015;15:71.","journal-title":"BMC Cancer"},{"key":"8077_CR108","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1083\/jcb.119.3.629","volume":"119","author":"F Bussolino","year":"1992","unstructured":"Bussolino F, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629\u201341.","journal-title":"J Cell Biol"},{"key":"8077_CR109","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/S1535-6108(03)00085-0","volume":"3","author":"S Pennacchietti","year":"2003","unstructured":"Pennacchietti S, et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003;3:347\u201361.","journal-title":"Cancer Cell"},{"key":"8077_CR110","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, et al. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024;42:3000\u201311.","journal-title":"J Clin Oncol"},{"key":"8077_CR111","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","volume":"36","author":"H Horinouchi","year":"2025","unstructured":"Horinouchi H, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025;36:583\u201391.","journal-title":"Ann Oncol"},{"key":"8077_CR112","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1158\/0008-5472.CAN-10-1623","volume":"71","author":"J Qi","year":"2011","unstructured":"Qi J, et al. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. Cancer Res. 2011;71:1081\u201391.","journal-title":"Cancer Res"},{"key":"8077_CR113","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.jtho.2016.06.013","volume":"11","author":"RS Heist","year":"2016","unstructured":"Heist RS, et al. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping. J Thorac Oncol. 2016;11:1242\u20135.","journal-title":"J Thorac Oncol"},{"key":"8077_CR114","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/1535-7163.MCT-21-0344","volume":"21","author":"M Bahcall","year":"2022","unstructured":"Bahcall M, et al. Combination of Type I and Type II MET Tyrosine Kinase Inhibitors as Therapeutic Approach to Prevent Resistance. Mol Cancer Ther. 2022;21:322\u201335.","journal-title":"Mol Cancer Ther"},{"key":"8077_CR115","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo G, et al. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC. Clin Cancer Res. 2020;26:2615\u201325.","journal-title":"Clin Cancer Res"},{"key":"8077_CR116","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","volume":"25","author":"K Suzawa","year":"2019","unstructured":"Suzawa K, et al. Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2019;25:1248\u201360.","journal-title":"Clin Cancer Res"},{"key":"8077_CR117","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.21037\/tlcr-22-176","volume":"11","author":"W Choi","year":"2022","unstructured":"Choi W, et al. MYC amplification-conferred primary resistance to capmatinib in a MET-amplified NSCLC patient: a case report. Transl Lung Cancer Res. 2022;11:1967\u201372.","journal-title":"Transl Lung Cancer Res"},{"key":"8077_CR118","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jtho.2020.01.027","volume":"15","author":"P Jamme","year":"2020","unstructured":"Jamme P, et al. Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. J Thorac Oncol. 2020;15:741\u201351.","journal-title":"J Thorac Oncol"},{"key":"8077_CR119","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1158\/0008-5472.CAN-09-3620","volume":"70","author":"U McDermott","year":"2010","unstructured":"McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res. 2010;70:1625\u201334.","journal-title":"Cancer Res"},{"key":"8077_CR120","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1158\/2159-8290.CD-16-0686","volume":"6","author":"M Bahcall","year":"2016","unstructured":"Bahcall M, et al. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016;6:1334\u201341.","journal-title":"Cancer Discov"},{"key":"8077_CR121","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","volume":"28","author":"M Apicella","year":"2018","unstructured":"Apicella M, et al. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Cell Metab. 2018;28:848\u2013e8656.","journal-title":"Cell Metab"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08077-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08077-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:01Z","timestamp":1778616181000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08077-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":121,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8077"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08077-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"666"}}